APTO

Aptose Biosciences
APTO

$0.57

2.9%

Market Cap: 10.3M

About: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Employees: 36

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

4% less funds holding

Funds holding: 28 [Q4 2023] → 27 (-1) [Q1 2024]

10.07% less ownership

Funds ownership: 16.51% [Q4 2023] → 6.44% (-10.07%) [Q1 2024]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

49% less capital invested

Capital invested by funds: $3.33M [Q4 2023] → $1.68M (-$1.65M) [Q1 2024]

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

780%

upside

Avg. target

$9.20

1,520%

upside

High target

$23

3,949%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	1,132%upside $7	Buy Reiterated	14 Jun 2024
Canaccord Genuity John Newman	956%upside $6	Buy Maintained	16 May 2024
Piper Sandler Edward Tenthoff	780%upside $5	Overweight Maintained	3 Apr 2024
HC Wainwright & Co. Joseph Pantginis	3,949%upside $23	Buy Maintained	27 Mar 2024
Piper Sandler Edward Tenthoff	780%upside $5	Overweight Maintained	1 Feb 2024

See Analyst Rankings

Financial journalist opinion

Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has received a deficiency letter (the "Deficiency Letter") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company's common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting.

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated SAN DIEGO and TORONTO, June 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. Tuspetinib (TUS) is being developed as a TUS + venetoclax (VEN) + hypomethylating agent (HMA) triple drug combination (or TUS+VEN+HMA triplet) as frontline therapy for newly diagnosed AML patients.

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Zacks Investment Research

Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equivalent in lieu thereof). Additionally, in a concurrent private placement, Aptose has issued unregistered series A warrants to purchase up to 3,855,000 common shares and series B warrants to purchase up to 3,855,000 common shares, each at an exercise price of $1.15 per share.

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Aptose has agreed to issue unregistered series A warrants to purchase up to 3,855,000 common shares and series B warrants to purchase up to 3,855,000 common shares, each at an exercise price of $1.15 per share.

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Susan Pietropaolo - MD, Corporate Communications and IR William Rice - Chairman, President and CEO Rafael Bejar - SVP and CMO Fletcher Payne - SVP, CFO, and CBO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon.

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

Aptose Reports Results for the First Quarter 2024

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will provide a corporate update webcast at 5:00 pm ET today, which will include slides focused on the new triplet pilot study expected to deliver clinical data in the second half of this year.

Aptose Reports Results for the First Quarter 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatment of newly diagnosed AML patients.

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Zacks Investment Research

What Makes Aptose Biosciences (APTO) a New Buy Stock

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Aptose Biosciences (APTO) a New Buy Stock

See News Rankings